# XGen Pharmaceuticals DJB, Inc. – FDA 483, Aug 22, 2019

Source: https://www.keypedia.com/records/483/xgen-pharmaceuticals-djb-inc/3e08ac8d-052b-42e4-b0c1-dcb1a49b7848

> FDA 483 for XGen Pharmaceuticals DJB, Inc. on August 22, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: XGen Pharmaceuticals DJB, Inc.
- Inspection Date: 2019-08-22
- Product Type: drugs
- Office Name: Division of Human and Animal Food Operations - East I
- Summary: An FDA inspection of X-Gen Pharmaceuticals Inc.'s corporate office in Horseheads, NY, revealed significant deficiencies in their postmarketing adverse drug experience (PADE) reporting system. The firm lacked adequate written procedures for the surveillance, receipt, and evaluation of adverse drug experiences, and failed to submit required adverse drug experience reports and annual reports in a timely manner. These issues indicate a systemic failure to comply with PADE regulations.

## Related Documents

- [483 - 2024-07-14](https://www.keypedia.com/records/483/xgen-pharmaceuticals-djb-inc/e382cce9-d874-4e94-9ad2-a26788f57402) — date: July 14, 2024
- [483 - 2024-06-14](https://www.keypedia.com/records/483/xgen-pharmaceuticals-djb-inc/62589896-47b7-4d27-a184-96ef9c6e9dff) — date: June 14, 2024

## Related Officers

- [Joanne M. Schlossin](https://www.keypedia.com/people/joanne-m-schlossin/5cb48b8a-d885-4b4f-8c60-d4714d65603d)
- [Investigator ](https://www.keypedia.com/people/karen-l-kosar/6e58be60-f8e3-44f3-8218-8acdde249724)

Company: https://www.keypedia.com/companies/xgen-pharmaceuticals-djb-inc/42cd8012-b30d-440e-b2c7-e0d2915c417a

Office: https://www.keypedia.com/offices/division-of-human-and-animal-food-operations-east-i/a807f00e-d780-40b8-b233-1eb92ece8961